Enzo Biochem logo

Enzo BiochemNYSE: ENZ

Profile

Sector:

Healthcare

Country:

United States

IPO:

12 June 1980

Next earnings report:

13 December 2024

Last dividends:

15 November 2024

Next dividends:

N/A
$52.24 M
-70%vs. 3y high
35%vs. sector
-vs. 3y high
-vs. sector
-86%vs. 3y high
37%vs. sector
-81%vs. 3y high
34%vs. sector

Price

pre-market | 49 min ago
$1.00-$0.01(-0.99%)
$7.53 M-$13.38 M

Analysts recommendations

Institutional Ownership

ENZ Latest News

ENZ Stock Up Following FY24 Earnings Uptick, Gross Margin Expands
zacks.com30 October 2024 Sentiment: POSITIVE

Enzo Biochem's overall topline benefits from revenue growth in the majority of its geographic regions.

Enzo Biochem Reports Fourth Quarter and Fiscal Year 2024 Results and Announces Cash Dividend
globenewswire.com29 October 2024 Sentiment: POSITIVE

FARMINGDALE, N.Y., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”) today announced financial results for the fiscal fourth quarter ended July 31, 2024 and the fiscal year ended July 31, 2024. The Company also announced that its board of directors had authorized a cash dividend of $0.10 per share of its common stock.

Enzo Biochem to pay $4.5 mln for failing to safeguard patient data
reuters.com13 August 2024 Sentiment: NEGATIVE

Enzo Biochem will pay $4.5 million to settle claims it failed to adequately safeguard personal and private health information of its patients, New York Attorney General Letitia James said on Tuedsay.

Enzo Biochem: Is This Time Finally Different?
seekingalpha.com17 July 2024 Sentiment: POSITIVE

Enzo Biochem shareholders frustrated with lack of capital returns following Clinical Labs sale to Labcorp Holdings. Stock trading near historic lows, but potential for attractive returns with simplified Life Sciences division and strong CEO incentives. Valuation potential of $2.00-3.22/share with $35m net cash and $75-120m business value, pending resolution of legal issues and potential share buybacks.

Zacks Initiates Coverage of Enzo Biochem With Neutral Recommendation
zacks.com20 June 2024 Sentiment: POSITIVE

Discover why Zacks rates Enzo Biochem as "Neutral", being the first on Wall Street to initiate coverage on the stock. Explore ENZ's notable revenue growth and financial health amid market challenges.

Enzo Biochem (ENZ) Q3 Earnings Improve Y/Y, Gross Margin Up
zacks.com14 June 2024 Sentiment: POSITIVE

Enzo Biochem's (ENZ) overall topline benefits from revenue growth in the majority of its geographic regions.

Enzo Biochem Reports Third Quarter Fiscal 2024 Results and Provides Business Update
globenewswire.com13 June 2024 Sentiment: POSITIVE

FARMINGDALE, N.Y., June 13, 2024 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”) today announced financial results for the fiscal third quarter ended April 30, 2024.

Enzo Biochem: Cleaned Up And Cash-Rich But Unloved
Seeking Alpha26 October 2023 Sentiment: POSITIVE

Enzo Biochem is a microcap company with a $30 million revenue run-rate Life Sciences business and $78-$85 million in cash. The company is likely being prepared for sale, with interest from potential acquirers and activists controlling 30% of voting shares. Enzo's focus on generating positive cash flow and enhancing shareholder value could lead to significant improvement in Life Sciences results.

Enzo Biochem, Inc. Announces Date of Special Meeting of Shareholders
GlobeNewsWire24 April 2023 Sentiment: NEGATIVE

FARMINGDALE, NY, April 24, 2023 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo Biochem” or the “Company”), a leading biosciences and diagnostics company, today announced that its special meeting of shareholders (the “Special Meeting”) to consider and vote on a proposal to approve the sale (the “Asset Sale”) of substantially all the assets and assignment of certain liabilities of its clinical laboratory business to Laboratory Corporation of America Holdings, a Delaware corporation (“Labcorp”) and adopt the Asset Purchase Agreement, dated as of March 16, 2023 (as such agreement may be amended from time to time, the “Asset Purchase Agreement”), by and among the Company, Enzo Clinical Labs, Inc., a New York corporation and Labcorp will be held on May 22, 2023 at 9:00 a.m. Eastern Time.

What type of business is Enzo Biochem?

Enzo Biochem, Inc., a life sciences company, engages in the labeling and detection technologies from DNA to whole cell analysis in the United States and internationally. The company offers labels, dyes, antibodies, genomic probes, immunoassays, biochemicals, and proteins are used to label, detect, and visualize a biological target of interest in drug discovery exploration and drug development process development. Its proprietary products and technologies play roles in translational research and drug development areas, including cell biology, genomics, assays, immunohistochemistry, and small molecule chemistry. The company licenses its technology. It serves academic researchers, clinical researchers, biotechnology and pharmaceutical companies, and diagnostic manufacturers. Enzo Biochem, Inc. was incorporated in 1976 and is headquartered in Farmingdale, New York.

What sector is Enzo Biochem in?

Enzo Biochem is in the Healthcare sector

What industry is Enzo Biochem in?

Enzo Biochem is in the Diagnostics & Research industry

What country is Enzo Biochem from?

Enzo Biochem is headquartered in United States

When did Enzo Biochem go public?

Enzo Biochem initial public offering (IPO) was on 12 June 1980

What is Enzo Biochem website?

https://www.enzo.com

Is Enzo Biochem in the S&P 500?

No, Enzo Biochem is not included in the S&P 500 index

Is Enzo Biochem in the NASDAQ 100?

No, Enzo Biochem is not included in the NASDAQ 100 index

Is Enzo Biochem in the Dow Jones?

No, Enzo Biochem is not included in the Dow Jones index

When was Enzo Biochem the previous earnings report?

No data

When does Enzo Biochem earnings report?

The next expected earnings date for Enzo Biochem is 13 December 2024